241 related articles for article (PubMed ID: 34296214)
1. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
Negi A; Voisin-Chiret AS
Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
[TBL] [Abstract][Full Text] [Related]
3. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
[TBL] [Abstract][Full Text] [Related]
4. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
5. Discovery of PROTAC BCL-X
Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
[TBL] [Abstract][Full Text] [Related]
6. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
[TBL] [Abstract][Full Text] [Related]
7. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
bioRxiv; 2024 Mar; ():. PubMed ID: 38464204
[TBL] [Abstract][Full Text] [Related]
8. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
[TBL] [Abstract][Full Text] [Related]
9. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X
Zhang X; Thummuri D; He Y; Liu X; Zhang P; Zhou D; Zheng G
Chem Commun (Camb); 2019 Dec; 55(98):14765-14768. PubMed ID: 31754664
[TBL] [Abstract][Full Text] [Related]
10. MDM2-BCL-X
Chang M; Gao F; Chen J; Gnawali G; Wang W
Acta Mater Med; 2022 Jul; 1(3):333-342. PubMed ID: 36910255
[TBL] [Abstract][Full Text] [Related]
11. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Novel BCL-X
Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M
Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252
[TBL] [Abstract][Full Text] [Related]
14. A selective BCL-X
Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
[TBL] [Abstract][Full Text] [Related]
15. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
17. Targeting BCL-XL in fibrolamellar hepatocellular carcinoma.
Shebl B; Ng D; Lalazar G; Rosemore C; Finkelstein TM; Migler RD; Zheng G; Zhang P; Jiang CS; Qureshi A; Vaughan R; Yarchoan M; de Jong YP; Rice CM; Coffino P; Ortiz MV; Zhou D; Simon SM
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 36073545
[TBL] [Abstract][Full Text] [Related]
18. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
[TBL] [Abstract][Full Text] [Related]
20. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2
Moncsek A; Al-Suraih MS; Trussoni CE; O'Hara SP; Splinter PL; Zuber C; Patsenker E; Valli PV; Fingas CD; Weber A; Zhu Y; Tchkonia T; Kirkland JL; Gores GJ; Müllhaupt B; LaRusso NF; Mertens JC
Hepatology; 2018 Jan; 67(1):247-259. PubMed ID: 28802066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
